

## Bibliographic Information

**Remedies for endothelin-induced diseases.** Yuyama, Hironori; Fujimori, Akira; Sanagi, Masanao; Harada, Hironori; Koakutsu, Akiko; Mori, Mikiko; Yamamoto, Nobuyuki. (Yamanouchi Pharmaceutical Co., Ltd., Japan). PCT Int. Appl. (2001), 27 pp. CODEN: PIXXD2 WO 2001060370 A1 20010823 Designated States W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM. Designated States RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, ML, MR, NE, SN, TD, TG. Patent written in Japanese. Application: WO 2000-JP7573 20001027. Priority: JP 2000-37313 20000216; JP 2000-37314 20000216. CAN 135:200444 AN 2001:617825 CAPLUS

## Patent Family Information

Patent No.	Kind	Date	Application No.	Date
WO 2001060370	A1	20010823	WO 2000-JP7573	20001027
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000079614	A5	20010827	AU 2000-79614	20001027
JP 2001302514	A	20011031	JP 2000-328374	20001027
JP 3832229	B2	20061011		
CA 2395711	A1	20020718	CA 2000-2395711	20001027
EP 1256344	A1	20021113	EP 2000-970160	20001027
EP 1256344	B1	20061220		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
BR 2000017120	A	20030114	BR 2000-17120	20001027
HU 200204139	A2	20030528	HU 2002-4139	20001027
US 6774131	B1	20040810	US 2002-181489	20020719
JP 2006176542	A	20060706	JP 2006-90667	20060329
<u>Priority Application</u>				
JP 2000-37313	A	20000216		
JP 2000-37314	A	20000216		
WO 2000-JP7573	W	20001027		
JP 2000-328374	A3	20001027		

## Abstract

Disclosed are drug compns. for treatment of prostatic cancer, contg. as the active ingredient N-[6-methoxy-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]-2-phenyl-ethenesulfonamide (I) or pharmaceutically acceptable salts thereof. The inhibitory effect of compd. I on endothelin-1 (ET-1)-induced cell proliferation in hormone-independent human prostate cancer cell line (PPC-1).